What is HC Wainwright’s Estimate for SGMO FY2028 Earnings?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Analysts at HC Wainwright dropped their FY2028 earnings per share estimates for Sangamo Therapeutics in a research note issued to investors on Thursday, April 2nd. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will post earnings per share of $0.27 for the year, down from their prior estimate of $0.28. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ FY2029 earnings at $0.40 EPS and FY2030 earnings at $0.57 EPS.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Monday, March 30th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.12). The company had revenue of $14.23 million during the quarter, compared to analyst estimates of $40.25 million. Sangamo Therapeutics had a negative return on equity of 1,070.18% and a negative net margin of 310.81%.

SGMO has been the topic of a number of other reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Sangamo Therapeutics in a report on Thursday, January 22nd. Wall Street Zen lowered Sangamo Therapeutics to a “strong sell” rating in a research note on Saturday, January 31st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $5.50.

Sangamo Therapeutics Stock Performance

NASDAQ SGMO opened at $0.30 on Friday. The company has a fifty day simple moving average of $0.38 and a two-hundred day simple moving average of $0.47. The stock has a market cap of $124.32 million, a P/E ratio of -0.68 and a beta of 1.49. Sangamo Therapeutics has a 12-month low of $0.21 and a 12-month high of $0.84.

Hedge Funds Weigh In On Sangamo Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in Sangamo Therapeutics during the 4th quarter valued at approximately $56,000. Invesco Ltd. increased its stake in shares of Sangamo Therapeutics by 23.7% in the fourth quarter. Invesco Ltd. now owns 1,000,292 shares of the biopharmaceutical company’s stock worth $420,000 after acquiring an additional 191,561 shares during the period. Oracle Investment Management Inc. raised its holdings in shares of Sangamo Therapeutics by 3.1% during the fourth quarter. Oracle Investment Management Inc. now owns 1,035,742 shares of the biopharmaceutical company’s stock worth $435,000 after purchasing an additional 31,018 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Sangamo Therapeutics during the fourth quarter worth $77,000. Finally, Luminus Management LLC lifted its position in Sangamo Therapeutics by 363.5% during the fourth quarter. Luminus Management LLC now owns 1,158,761 shares of the biopharmaceutical company’s stock valued at $487,000 after purchasing an additional 908,761 shares during the period. 56.92% of the stock is owned by hedge funds and other institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.